Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ernst and Young round table identifies new investors

This article was originally published in Clinica

Executive Summary

There is a new type of investor in the biotech industry, according to a panel assembled as part of the 12th Annual Biotechnology Industry Report, published by the global accountancy company, Ernst & Young. There are those, particularly in Europe, who are following a trend set in the early 1990s in the US, by investing solely in the sector. Others have made an investment calculation based on the results of clinical trials, despite the fact that those trials may not be favourable to the companies concerned.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts